Pascal Deschatelets Sells 78,907 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Pascal Deschatelets sold 78,907 shares of the business’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $42.35, for a total transaction of $3,341,711.45. Following the completion of the transaction, the insider now owns 1,115,983 shares in the company, valued at approximately $47,261,880.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Pascal Deschatelets also recently made the following trade(s):

• On Monday, April 8th, Pascal Deschatelets sold 69,107 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19.

Apellis Pharmaceuticals Stock Up 0.5 %

APLS stock opened at $42.52 on Friday. The business has a 50 day moving average of $53.91 and a 200 day moving average of $57.32. The firm has a market cap of $5.16 billion, a PE ratio of -12.29 and a beta of 0.97. Apellis Pharmaceuticals, Inc. has a twelve month low of $19.83 and a twelve month high of $94.75. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). The firm had revenue of $172.33 million during the quarter, compared to the consensus estimate of $163.37 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The company’s revenue was up 284.3% on a year-over-year basis. During the same period last year, the company earned ($1.56) earnings per share. On average, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in APLS. First Horizon Advisors Inc. increased its position in shares of Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after acquiring an additional 265 shares in the last quarter. Future Financial Wealth Managment LLC purchased a new stake in Apellis Pharmaceuticals during the 1st quarter valued at $29,000. Covestor Ltd increased its holdings in shares of Apellis Pharmaceuticals by 564.2% in the 3rd quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after purchasing an additional 677 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Apellis Pharmaceuticals in the first quarter worth $89,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Apellis Pharmaceuticals by 29.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock valued at $115,000 after purchasing an additional 687 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Analysts Set New Price Targets

APLS has been the topic of a number of recent analyst reports. Raymond James lifted their price objective on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research report on Thursday, January 11th. HC Wainwright reiterated a “buy” rating and issued a $92.00 price target on shares of Apellis Pharmaceuticals in a report on Wednesday. Wedbush reduced their price objective on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Robert W. Baird reaffirmed an “outperform” rating and set a $81.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Finally, Oppenheimer increased their price target on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 30th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $76.67.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).